VioQuest Pharmaceuticals Announces Phase I/IIa Trial For Akt Inhibitor VQD-002
Akt InhibitorClinical Trial
VioQuest Pharmaceuticals announced that it will proceed with Phase II trials later this year with its direct Akt inhibitor VQD-002.
Ongoing trials in patients with refractory leukemia and solid tumors are expected to complete phase I enrollment in June 2007. VQD-002 is a novel direct inhibitor of activation of Akt, a serine-threonine kinase that is over expressed and or hyperactivated in resistant and refractory tumors as well as in aggressive hematologic malignancies. Phase I/IIa clinical trials are currently ongoing at the MD Anderson Cancer Center, Houston, TX, and at the H. Lee Moffitt Cancer Center, Tampa, FL.
The objectives of the clinical trials in hematologic malignancies conducted at MD Anderson and H. Lee Moffitt Cancer Center, include the evaluation of VQD-002's safety profile, pharmacokinetic (PK) and pharmacodynamic (PD) parameters, and the effects VQD-002 has on Akt modulation. Eleven patients have been enrolled in the ongoing leukemia trial. In the leukemia trial, reductions in malignant cells (peripheral blast cells) have been seen in several of the patients following initial therapy. Some patients have had improvements observed in parameters of their bone marrow function (increases in platelet and neutraphil counts).
The objectives of the clinical trial in solid tumors conducted at H. Lee Moffitt Cancer Center, include the evaluation of VQD-002's safety profile, pharmacokinetic (PK) and pharmacodynamic (PD) parameters, and the effects VQD- 002 has on Akt modulation. Eleven patients with solid tumors have been enrolled in the phase I portion of the ongoing solid tumor trial. Several of these patients, refractory to prior standard therapy and who were screened and selected for study based on the high level of Akt expression in their tumors, have shown stable disease on study.